In Friday’s Wall Street session, Regulus Therapeutics Inc (NASDAQ:RGLS) shares traded at $8.21, up 7.88% from the previous session.
RGLS stock price is now 0.02 away from the 50-day moving average and May 08 AMC away from the 200-day moving average. The market capitalization of the company currently stands at $545.56M.
With the price target enhanced from $3 to $6, Wells Fargo Upgraded its rating from Equal Weight to Overweight for Regulus Therapeutics Inc (NASDAQ: RGLS). On August 02, 2024, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $7, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, Klassen Preston, President & Head of R & D bought 12,000 shares of the company’s stock on Jun 03 ’25. The stock was bought for $95,852 at an average price of $7.99. Upon completion of the transaction, the President & Head of R & D now directly owns 48,055 shares in the company, valued at $0.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 30 ’25, Chief Executive Officer Hagan Joseph P bought 50,000 shares of the business’s stock. A total of $54,260 was incurred on buying the stock at an average price of $1.09. This leaves the insider owning 260,808 shares of the company worth $2.14 million. A total of 17.20% of the company’s stock is owned by insiders.
During the past 12 months, Regulus Therapeutics Inc has had a low of $0.83 and a high of $8.35. The fifty day moving average price for RGLS is $6.389 and a two-hundred day moving average price translates $2.69575 for the stock.
The latest earnings results from Regulus Therapeutics Inc (NASDAQ: RGLS) was released for 2025-03-31.
